A Phase II Study of AK104 Combination With Lenvatinib Versus Lenvatinib for Second-line HCC
This is a Phase II, randomized, open-label, global, multi-center study to compare the efficacy and safety of AK104 in combination with lenvatinib versus lenvatinib in patients with advanced hepatocellular carcinoma who have progressed on the first line treatment of atezolizumab and bevacizumab.
HCC|Hepatocellular Carcinoma
BIOLOGICAL: AK104+lenvatinib|DRUG: lenvatinib
Objective Response Rate (ORR) per RECIST v1.1 by Blinded Independent Central Review (BICR), Proportion of subjects who have a complete or partial response relative to baseline as assessed by BICR according to RECIST v1.1., Up to 24 months
Overall Survival (OS), OS is defined as the time from randomization to death due to any cause., Up to 24 months|Progression-free survival (PFS) assessed by investigator per RECIST v1.1, PFS is defined as the time from randomization till the first documented disease progression (Per RECIST v1.1 assessed by the investigator) or death due to any cause, whichever occurs first., Up to 24 months|Duration of Response (DOR) assessed by investigator per RECIST v1.1, DOR means time measured from the date of partial or complete response to therapy until the cancer progresses based on RECIST v1.1 criteria., Up to 24 months|Time to Response (TTR) assessed by investigator per RECIST v1.1, TTR refers to Time to Response., Up to 24 months|Number of participants with adverse event (AE), The number of participants experiencing an Adverse Event (AE) and the severity of AEs will be assessed. AE refers to any untoward medical occurrence or deterioration of existing medical event after the subject signed the ICF, whether or not considered related to the study treatment., Up to 24 months
This is a Phase II, randomized, open-label, global, multi-center study to compare the efficacy and safety of AK104 in combination with lenvatinib versus lenvatinib in patients with advanced hepatocellular carcinoma who have progressed on the first line treatment of atezolizumab and bevacizumab.